ProShare Advisors’s Arcturus Therapeutics ARCT Stock Holding History

ProShare Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-6,064	Closed	-$205K	–	1859
2024 Q1	$205K	Buy	+6,064	New	+$215K	﹤0.01%	1655
2022 Q1	–	Sell	-8,322	Closed	-$308K	–	2208
2021 Q4	$308K	Sell	8,322 -7	-0.1%	-$285	﹤0.01%	1767
2021 Q3	$398K	Sell	8,329 -1,879	-18%	-$84.2K	﹤0.01%	1352
2021 Q2	$345K	Buy	10,208 +1,256	+14%	+$42.5K	﹤0.01%	1794
2021 Q1	$370K	Buy	8,952 +296	+3%	+$17.6K	﹤0.01%	1665
2020 Q4	$375K	Buy	+8,656	New	+$586K	﹤0.01%	1455
2016 Q4	–	Sell	-2,483	Closed	-$43K	–	1743
2016 Q3	$43K	Sell	2,483 -448	-15%	-$14.5K	﹤0.01%	1445
2016 Q2	$92K	Buy	2,931 +59	+2%	+$1.86K	﹤0.01%	1526
2016 Q1	$76K	Sell	2,872 -271	-9%	-$9.18K	﹤0.01%	1534
2015 Q4	$138K	Buy	+3,143	New	+$142K	﹤0.01%	1605

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

ProShare Advisors's ARCT Position: Q2 2024 in Review

ProShare Advisors sold out of Arcturus Therapeutics (ARCT) in Q2 2024, closing a stake of 6,064 shares — an estimated $205K sold.

ProShare Advisors first reported a position in ARCT in Q4 2015 and held it in 10 quarters. The position peaked at $398K in Q3 2021. 171 funds tracked by Wall St. Rank hold ARCT as of Q2 2024.

ProShare Advisors reported no remaining Arcturus Therapeutics position as of Q2 2024 after selling out during the quarter.
ProShare Advisors sold 6,064 Arcturus Therapeutics shares in Q2 2024, an estimated $205K.
ProShare Advisors first reported a position in Arcturus Therapeutics in Q4 2015 and held it in 10 quarters.
ProShare Advisors's Arcturus Therapeutics position peaked at $398K in Q3 2021.
171 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2024.

Based on ProShare Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.